VivoSeq
Oncology

Acute Leukemia of Ambiguous Lineage

25

Pipeline Programs↗

4

Active Trials↗

17

Companies Involved↗

Acute Leukemia of Ambiguous Lineage is an emerging landscape with 25 programs across 17 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Teva, Alnylam Pharmaceuticals. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1Teva logo

Teva

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2S

Stason

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

21 of 24 classified programs — the dominant modality here.

13%ALL OTHERSProtein / enzyme28%Monoclonal antibody14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 96% of 25 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Not yet recruiting1 · 20%
Completed1 · 20%

Clinical Trials

Trial Activity

Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06991920·50 enrolled
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT03194932·62 enrolled
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06317662·153 enrolled
Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia or High-Grade Myeloid Neoplasms: A Randomized Pilot Study
Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07094750·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)